Stress-related emotional disturbances in patients with cardiovascular diseases

Acute and chronic stress, as well as emotional disturbances as a consequence of stressful situations, are significant risk factors for the development and progression of some of acute and chronic non-communicable diseases, including cardiovascular diseases (CVD), among which the most common are arterial hypertension, chronic heart failure and atherosclerotic CVD. Specific emotional disturbances that arise after exposure to significant traumatic or stressful situations include acute and post-traumatic stress disorder. When a stress factor does not reach high intensity or significance, adjustment disorder may develop. Stress-related emotional disturbances significantly affect other CVD risk factors, reduce patients’ adherence to healthy lifestyle changes and drug therapy, deteriorate quality of life and increase the risk of disability. The urgency of identifying and managing post-stress emotional disturbances in the practice of internists is caused by high frequency of these disturbances in outpatient patients. It is especially important to manage and prevent these disturbances in patients with CVD due to increased number of adverse outcomes resulting from this combination. Treatment of emotional disturbances resulting from stressful situations includes both drug and non-drug methods. Antidepressants and benzo-diazepine anxiolytics are the main classes among the drugs used to treat post-stress emotional disorders. However, the prescription of these drugs requires taking into account a wide range of possible side effects, especially in patients with CVD. The choice of drugs with a favourable safety profile and a rapid onset of sedative and anti-anxiety effects is a key element in the modern effective patient management strategy. Tofisopam and buspirone are the most advanced of this group of drugs in therapeutic and cardiological practice.

1. Drapkina OM, Kontsevaya AV, Kalinina AM, Avdeev SM, Agaltsov MV, Alexandrova LM et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3235.

2. Drapkina OM, Shishkova VM, Kotova MB. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Guidelines for internists. Cardiovascular Therapy and Prevention. 2022;21(10):3438. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3438.

3. Porfiryev BN, Makrova EA. Natural and man-made disasters: consequences for the population and the economy. Economics and Management. 2014;(4):4–15. (In Russ.) Available at: https://elibrary.ru/sdfvyd.

4. Александровский ЮА, Незнанов НГ (ред.). Психиатрия: национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2018. 1008 с.

5. Jeste DP, Lieberman FA, Fassler TD, Peele R, Benson RS, Young ML et al. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Arlington, VA: American Psychiatric Publishing; 2013. 970 р. Available at: https://repository.poltekkes-kaltim.ac.id/657/1/Diagnostic%20and%20statistical%20manual%20of%20mental%20disorders%20_%20DSM-5%20(%20PDFDrive.com%20).pdf.

6. Shishkova VN. Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy. Meditsinskiy Sovet. 2023;17(13):256–262. (In Russ.) https://doi.org/10.21518/ms2023-230.

7. Shishkova VN. Cognitive and emotional disorders in patients with chronic heart failure: prospects for detection and correction. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):87–93. (In Russ.) https://doi.org/10.14412/2074-2711-2022-3-87-93.

8. Chazov EI, Oganov RG, Pogosova GV, Shalnova SA, Skazin NV, Romasenko LV. Clinical and epidemiological program for studying depression in cardiological practice in patients with arterial hypertension and coronary heart disease (COORDINATE): results of the therapeutic part of a multicenter study. Serdtse: Zhurnal dlya Praktikuyushchikh Vrachey. 2007;6(1):44–48. (In Russ.) Available at: https://elibrary.ru/odsuil.

9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. https://doi.org/10.1016/s0140-6736(04)17018-9.

10. Shishkova VN, Kotova MB, Kapustina LA, Imamgayazova KE. Issues of pathogenesis of cognitive and psychoemotional disorders in patients with cardiovascular and metabolic diseases. Therapy. 2021;50(8):158–163. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/41008.

11. Wirtz PH, von Känel R. Psychological Stress, Inflammation, and Coronary Heart Disease. Curr Cardiol Rep. 2017;19(11):111. https://doi.org/10.1007/s11886-017-0919-x.

12. Liu MY, Li N, Li WA, Khan H. Association between psychosocial stress and hypertension: a systematic review and meta-analysis. Neurol Res. 2017;39(6):573–580. https://doi.org/10.1080/01616412.2017.1317904.

13. Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w.

14. Mehta PK, Sharma A, Bremner JD, Vaccarino V. Mental Stress-Induced Myocardial Ischemia. Curr Cardiol Rep. 2022;24(12):2109–2120. https://doi.org/10.1007/s11886-022-01821-2.

15. Kennedy E, Niedzwiedz CL. The association of anxiety and stress-related disorders with C-reactive protein (CRP) within UK Biobank. Brain Behav Immun Health. 2021;19:100410. https://doi.org/10.1016/j.bbih.2021.100410.

16. Shishkova VN, Dranitsyna YuG, Drapkina OM. Algorithms for the management of patients with anxiety in the internist’s practice. Cardiovascular Therapy and Prevention. 2023;22(2):3526. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3526.

17. Shishkova V.N. Simple and effective solutions in the correction of anxiety and stress. Meditsinskiy Sovet. 2023;17(3):161–167. (In Russ.) https://doi.org/10.21518/ms2023-023.

18. Shishkova VN. Strategy for the management and prevention of psychoemotional disorders in the GP’s practice. Meditsinskiy Sovet. 2023;17(6):76–82. (In Russ.) https://doi.org/10.21518/ms2023-077.

19. Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012;1461:111–118. https://doi.org/10.1016/j.brainres.2012.04.032.

20. Bykov YuV, Bekker RA. Buspirone in the practice of a psychiatrist: is it only an anxiolytic? Psikhiatriya i Psikhofarmakoterapiya. 2017;19(5):32–52. (In Russ.) Available at: https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/239514/239510/.

21. Levin OS. The use of buspirone in clinical practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(4):83–87. (In Russ.) https://doi.org/10.17116/jnevro20151154183-87.

22. Dyukova GM, Saksonova EV, Golubev VL. Grandaxin in neurological practice. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2009;109(9):44–48. (In Russ.) Available at: https://elibrary.ru/lbeziz.

23. Vein AM, Artemenko AR, Okshin VYu, Pomortseva IV. The effectiveness of Grandaxin in the correction of psychovegetative disorders. Clinical Medicine (Russian Journal). 1999;77(6):41–45. (In Russ.)

24. Dyukova GM. Grandaxin in clinical practice. Lechenie Nervnykh Bolezney. 2005;16(2):25–29. (In Russ.) Available at: https://medi.ru/info/3098/.

25. Statsenko ME, Govorukha OA. The effect of Grandaxin on the quality of life and the rate of rehabilitation of patients with heart failure who have suffered a myocardial infarction. Yuzhno-Rossiyskiy Meditsinskiy Zhurnal. 2003;(5-6):13–21. (In Russ.) Available at: http://attic.volgmed.ru/publishing/lv/s/2004/2/lv-2004-2-023.pdf.

26. Skvortsov KYu, Golovacheva TV. Effectiveness of tofizopam (grandaxin) in the treatment of coronary heart disease: clinical and instrumental confirmation. Clinical Pharmacology and Therapy. 2008;10(1):53–55. (In Russ.) Available at: https://medi.ru/info/1371/.

27. Arushanyan EB, Bayda (Mastyagina) OA, Mastyagin SS, Popov AV. Chronobiological peculiarities of tofisopam action on human heart rate variability. Experimental and Clinical Pharmacology. 2005;68(4):36–39. (In Russ.) Available at: http://ekf.folium.ru/index.php/ekf/article/view/1146.

28. Kuleshova EV. The use of tofizopam (grandaxin) for the treatment of patients with coronary heart disease. Clinical Pharmacology and Therapy. 2000;9(5):53–55. (In Russ.) Available at: https://medi.ru/info/8089/.

29. Yarygin NV, Nikulin VV, Likutina AI. The experience of using Grandaxin in the correction of pre-examination stress in students of higher educational institutions. Farmateka. 2005;(13):139–142. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/6273.